SEC Form 4 · accession 0001562180-15-000660
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Anderson
Officer — See Remarks
Period of report
Aug 10, 2015
Accepted (ET)
Aug 11, 2015 · 11:21 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 10, 2015 | S | 3,480 | $67.66 | D | 2,520 | D | |
| Common StockF3 | Aug 10, 2015 | S | 1,220 | $67.14 | D | 1,300 | D | |
| Common StockF4 | Aug 10, 2015 | S | 1,300 | $65.34 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $67.29 USD to $68.29 USD. The price reported above reflects the weighted average sale price.
- F3This transaction was executed in multiple trades at prices ranging from $67.045 USD to $67.28 USD. The price reported above reflects the weighted average sale price.
- F4This transaction was executed in multiple trades at prices ranging from $65.21 USD to $66.20 USD. The price reported above reflects the weighted average sale price.